Todd Davis: Approval of Verona Pharma’s Ohtuvayre
Todd Davis, CEO at Ligand Pharmaceuticals, shared on LinkedIn:
“When I stepped in as CEO of Ligand Pharmaceuticals in December 2022 we had six key commercial-stage products driving Ligand’s financial performance. Today that number stands at 11 with the approval of Verona Pharma’s Ohtuvayre, the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in adult patients in more than 20 years.
I am excited to see the positive momentum across Ligand’s broader portfolio which now includes more than 30 marketed products, over 10 assets with an NDA submission or in Phase 3, and over 15 assets in Phase 2 development.
Read Ligand’s announcement on the Ohtuvayre FDA approval here.”
Source: Todd Davis/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023